Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIBS feasibility trial in primary care for irritable bowel syndrome
2009-013426-16Phase 4Completed
- Sponsor
- University of Southampton
- Start
- Oct 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mebeverine, methylcellulose and Placebo-COD Research Private Ltd in irritable bowel syndrome (IBS) (3 arms), sponsored by University of Southampton. Primary endpoints: IBS Symptom Severity Score and IBS Quality of Life. Started Oct 2009; status: completed.
02
Drugs
mebeverinemethylcellulosePlacebo-COD Research Private Ltd
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2009-013426-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013426-16.